

TWO DECADES OF PROGRESS AGAINST MULTIPLE MYELOMA

Most Recent Stats At-A-Glance


2021 U.S. ESTIMATES

34,920 **12,410**
New Cases Deaths

FDA APPROVED THERAPIES (AUG 1, 2020-JUL 31, 2021)

- 1  Immunotherapy
- 1  Molecularly Targeted Therapy
- 1  Chemotherapy

Percent Decrease in Multiple Myeloma Deaths



FDA Approved Drugs to Treat Multiple Myeloma

2001

6



2021

20



Multiple myeloma causes abnormal growth of plasma cells, which are blood cells that make antibodies to protect against infections. In 2021, nearly 35,000 Americans are expected to be diagnosed with multiple myeloma, and more than 12,000 are expected to die from it. Thanks to the unprecedented progress toward developing new precision-medicine-based treatments, mortality rates of multiple myeloma have declined 21 percent in the past two decades. In 2001, there

were only six FDA-approved drugs—all cytotoxic chemotherapeutics—to treat multiple myeloma patients. Today, clinicians have 20 FDA-approved drugs—of which 13 are molecularly targeted therapeutics or immunotherapeutics—at their disposal to treat multiple myeloma. In 2021, FDA approved a revolutionary new immunotherapeutic, the first BCMA-targeted CAR T-cell therapy, to treat patients with multiple myeloma.